Ethicann Pharmaceuticals has reformulated an approved drug (Sativex) to treat MS spasticity, making it safer and removing its 50% ethanol. A dog pharmacokinetic PK study showed that EPI-002 gives comparable blood levels as Sativex. Ethicann is using an abbreviated Health Canada approval pathway requiring only human bioequivalence, which can be used in Germany, UK and Europe for rapid approvals.